Illumina Fined More Than $400 Million in Europe for Closing Grail Deal Early
Wall Street Journal
The European Union’s antitrust watchdog fined the company with the maximum allowable amount for wrapping up its acquisition of the cancer-test developer while the agency was still reviewing it.